218 related articles for article (PubMed ID: 31384627)
1. Neuroendocrine Tumors in Pediatrics.
Farooqui ZA; Chauhan A
Glob Pediatr Health; 2019; 6():2333794X19862712. PubMed ID: 31384627
[TBL] [Abstract][Full Text] [Related]
2. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
3. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability.
Castle JT; Levy BE; Chauhan A
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291833
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.
Singh S; Asa SL; Dey C; Kennecke H; Laidley D; Law C; Asmis T; Chan D; Ezzat S; Goodwin R; Mete O; Pasieka J; Rivera J; Wong R; Segelov E; Rayson D
Cancer Treat Rev; 2016 Jun; 47():32-45. PubMed ID: 27236421
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
Hendifar AE; Marchevsky AM; Tuli R
J Thorac Oncol; 2017 Mar; 12(3):425-436. PubMed ID: 27890494
[TBL] [Abstract][Full Text] [Related]
8. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
Boudreaux JP; Klimstra DS; Hassan MM; Woltering EA; Jensen RT; Goldsmith SJ; Nutting C; Bushnell DL; Caplin ME; Yao JC;
Pancreas; 2010 Aug; 39(6):753-66. PubMed ID: 20664473
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs).
Maione F; Chini A; Milone M; Gennarelli N; Manigrasso M; Maione R; Cassese G; Pagano G; Tropeano FP; Luglio G; De Palma GD
Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33923121
[TBL] [Abstract][Full Text] [Related]
10. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.
Saavedra C; Barriuso J; McNamara MG; Valle JW; Lamarca A
Cancer Manag Res; 2019; 11():7537-7556. PubMed ID: 31496810
[TBL] [Abstract][Full Text] [Related]
12. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.
Hilal T
Ther Adv Med Oncol; 2017 Mar; 9(3):189-199. PubMed ID: 28344664
[TBL] [Abstract][Full Text] [Related]
13. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
14. Emerging use of everolimus in the treatment of neuroendocrine tumors.
Gajate P; Martínez-Sáez O; Alonso-Gordoa T; Grande E
Cancer Manag Res; 2017; 9():215-224. PubMed ID: 28684922
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment for gastrointestinal neuroendocrine tumors.
Eto K; Yoshida N; Iwagami S; Iwatsuki M; Baba H
Ann Gastroenterol Surg; 2020 Nov; 4(6):652-659. PubMed ID: 33319155
[TBL] [Abstract][Full Text] [Related]
16. Management of neuroendocrine tumors: current and future therapies.
Öberg KE
Expert Rev Endocrinol Metab; 2011 Jan; 6(1):49-62. PubMed ID: 30764035
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
18. Ampullary and Pancreatic Neuroendocrine Tumors: A Series of Cases and Review of the Literature.
Matli VVK; Wellman G; Jaganmohan S; Koticha K
Cureus; 2022 Jan; 14(1):e21657. PubMed ID: 35111492
[TBL] [Abstract][Full Text] [Related]
19. Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors.
Gangi A; Anaya DA
Curr Treat Options Oncol; 2020 Aug; 21(11):88. PubMed ID: 32862334
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
